Ombitasvir/Paritaprevir/Ritonavir plus Dasabuvir are Safety and Eficacy for Treating HCV GT1 and 4 Infection in Patients with Severe Renal Impairment or End-Stage Renal Disease: A Mulcicenter Experience
Rozas Gomez, I. Fernández, M.D. Pérez Valderas, G. Castellano, Estebes Hernandez, Diego Rincón, M. J. Devesa, Carmen de Mendoza Fernández, M. Ortiz, Adriana Ahumada, F. Cuenca, Maria Clara Costa Calvo(Universidad del Zulia)
Cited by 8
Related Papers
Polycystic Ovary Syndrome, Insulin Resistance, and Obesity: Navigating the Pathophysiologic Labyrinth
|International Journal of Reproductive Medicine|2014|451
Efficacy of senna versus lactulose in terminal cancer patients treated with opioids
|Journal of Pain and Symptom Management|1998|95
All‐oral direct‐acting antiviral therapy against hepatitis C virus (HCV) in human immunodeficiency virus/HCV–coinfected subjects in real‐world practice
|Hepatology|2018|79
Prevalence and Associated Factors of Insulin Resistance in Adults from Maracaibo City, Venezuela
|Advances in Preventive Medicine|2016|72